Tag: encompassing
Breaking News
HSM Advisory and Fujitsu Highlight Paradigm Shift in the Ways we Work in Global Research on Hybrid Work
 |
 |
Video message from Lynda Gratton and Hiramatsu Hiroki: https://www.youtube.com/watch?v=bosMD9fY4OU&feature=youtu.be
You can watch the video message from Lynda Gratton and Hiramatsu Hiroki from the below.
Lynda Gratton, Professor of Management Practice at London Business School and founder of HSM Advisory comments "We are pleased to be working with our partner Fujitsu to conduct this very important study. Through a series of interviews and focus group sessions conducted as input to this report, we gained new insights into how companies and managers are responding to the shift to hybrid work."
Hiroki Hiramatsu, CHRO at Fujitsu Limited comments, "With our successful 'Work Life Shift' initiative, Fujitsu has demonstrated its global leadership in the development and execution of new work styles that empower employees to realize their purpose, as well as the company's. As we strive to make hybrid working a reality, we remain focused on building autonomy and mutual trust between employees and the company. This report reflects our hope that the efforts of Fujitsu and HSM Advisory will contribute to the wellbeing and creativity of organizations and serve as a model for other organizations exploring new ways of working."
Moving forward, HSM Advisory and Fujitsu will continue to research, demonstrate, and implement hybrid working models that improve employee wellbeing and bring together diverse talent to drive innovation in the workplace and beyond.
A paradigm shift in the ways we work
The onset of the COVID-19 pandemic has served as a catalyst for change, challenging our most basic assumptions about how, when, and where we work. In response, many organizations have shifted to hybrid working, as employees grapple with the challenges of collaborating effectively across differences in both time and place. At the same time, with many employees enjoying greater autonomy, some organizations have leveraged the freedoms and flexibility offered by hybrid working models as a way to stand out amidst an increasingly competitive global labor market.
Designing new ways of working that drive both performance and wellbeing now represents a key concern for organizations looking to attract and retain top talent.
Survey Report Summary
HSM Advisory and Fujitsu began a joint study in August 2021 to gain better insight into these themes. In this joint study, Fujitsu and HSM Advisory surveyed how leaders, employees, and organizations are responding to the challenges and opportunities of hybrid work. Adopting a cross-organizational, global approach, we have developed a Sustainable High Performance model to support organizations in the redesign of work.
Through this research, we hope to share best practice and insights into redesigning work.
The research, undertaken in partnership with HSM Advisory from August to November 2021, consisted of interviews with 9 Fujitsu Leaders and 46 Fujitsu employees, and 4 Fujitsu Client leaders. This was followed by a survey, shared broadly through Fujitsu and HSM networks, which gathered data about the experiences of an additional 200 people. Further insights were derived from 8 leaders from HSM advisory partnerships.
Notes to editors:
Fujitsu introduced its own "Work Life Shift" initiative in July 2020 to redefine working styles for thousands of its employees. As employees worked from home, Fujitsu aimed to ensure that their experience was empowering, productive and creative, with the goal of boosting innovation and delivering new value to customers.
About Fujitsu
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
About HSM Advisory
HSM Advisory is a specialist research and advisory group founded by Professor Lynda Gratton of the London Business School. Lynda is one of the world's leading thinkers on the future of work and organizational behavior. For more information, please see https://hsm-advisory.com/.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHSM Advisory and Fujitsu Limited have published a joint research report on the current state and future of hybrid work, which sits at the convergence of the digital and real-world.
Sisram Medical Ltd Announces 2021 Record Annual Results
FINANCIAL HIGHLIGHTS
-- Revenue for the year ended December 31, 2021 was US$294.3 million, increased by 81.6% as compared to the revenue for the previous year.
-- Profit for the year ended December 31, 2021 was US$32.5 million, increased by 121.5% as compared to that for the previous year.
-- Net cash flows from operating activities for the year ended December 31, 2021 was US$32.4 million, increased by 25.8% as compared to that for the previous year.
-- Significant growth in all regions, mainly in North America and APAC. Revenue in North America for the year ended December 31, 2021 was US$112.0 million, increased by 105.8% as compared to that for the previous year. Revenue in APAC for the year ended December 31, 2021 was US$85.2 million, increased by 95.3% as compared to that for the previous year.
BUSINESS HIGHLIGHTS
-- R&D investments increased by 42.3% YoY to US$15.6 million with 2 new products launched: "Alma Duo" and "Alma PrimeX".
-- Continued the development of two new business lines - (i) Copulla - a new, innovative digital dentistry service; (ii) LMNT, a personal care brand, now launching a light-based skin rejuvenation home use device.
-- The Group entered into a sub-license agreement with Fosun Industrial for the commercialization of "RT002" Injectable, the new generation of neurotoxins for medical aesthetics use. The Group's existing injectables distribution operation, registered a revenue growth of 50.1% year over year.
-- The Group entered into an investment agreement at the amount of RMB 2.6 million for the establishment of Tianjin Xingsiyi, a research & development, technical services and supply operation for silk fibroin-sodium injectables and facial implant thread products.
-- The Group has acquired the entire share capital of Shanghai Foshion Medical System to further enhance its dental business line.
-- The Group purchased the remaining 40% equity interest in its Israeli distributor, Nova Medical. Upon completion, Nova Medical is a wholly-owned subsidiary of the Company, rebranded as Alma Israel.
FINAL DIVIDEND
-- The Board has resolved to declare a final dividend of HK$0.157 (inclusive of tax) per Share for the year ended December 31, 2021.
Business Growth Projection for 2022
Based on an increase in the demand for the Company's products and the backlog of orders as of December 31, 2021, barring any unforeseen circumstances or material change in market conditions, the Group expects to record a significant growth in revenue of over 35.0% in the first half of 2022 as compared to the revenue recorded in the corresponding period in 2021.
Record results, strong subsidiaries performance, overall geographic performance uptake, continued investments in R&D and strong business development momentum In 2021, Sisram's established global sales and distribution network recorded a total revenue of US$294.3 million for the Reporting Period, representing an increase of 81.6% when compared to 2020. All regions revenue increased substantially during the Reporting Period with North America demonstrating an increase of 105.8%, Asia Pacific with an increase of 95.3%, Latin America with an increase of 76.3%, Europe with an increase of 49.7% and Middle East & Africa with an increase of 45.2%.
The gross profit increased from US$90.3 million in 2020 to US$166.9 million in 2021, representing an increase of US$76.6 million. The gross profit margin in 2021 amounted to 56.7%, representing an increase of 1% compared to 55.7% in 2020. The establishment of direct operation offices in chosen territories has enabled the Company to shorten the supply chain, increase the average selling price, gain a higher brand visibility and ensure consistency among the communications with the target clientele. During 2021, revenue derived from direct sales has surpassed revenue derived from distributors with 62.0% attributed to the former and 38.0% to the latter.
For the Reporting Period, the Group recorded an adjusted net profit of US$40.3 million representing an increase of 100.0% when compared with the corresponding period of 2020. The adjusted net profit margin for the Reporting Period was 13.7%. The net cash flow from operating activities amounted to US$32.4 million, representing an increase of 25.8% when compared to 2020.
In 2021, Sisram continued its substantial R&D efforts, with 13% of corporate employees being R&D specialists. During the Reporting Period, R&D expense increased by 42.3% to US$15.6 million from US$11.0 million for the corresponding period in 2020. During the Reporting Period, the Group launched 2 new products, "Alma Duo" and "Alma PrimeX", as well as expanded two business lines, "Copulla" - a new, innovative digital dentistry service, and "LMNT", a personal care brand, now launching a light-based skin rejuvenation home use device.
Continued Investments in Digital Transformation and Production Ramp-up
In 2021, Sisram continued the development of its digital core architecture with vast investments in Information Systems and Digitalization, encompassing traditional ERP and CRM modules, IoT solutions for professional capital equipment, marketing automation and consumer access. Over the past 3 years (2019-2021), Sisram invested more than US$6.5 million in information systems, upgrading its ERP and CRM infrastructure, migrating to cloud-based systems to serve the entire growing and diverse eco-system and implementing new digital tools for Internal organization management, external engagement mechanisms between the organization and the market and cyber security.
On the operational front, Sisram focused on addressing the pandemic effect by investing in production ramp-up to accommodate the growing global demand and improve quality performances KPI's such as FPY (First Pass Yield) and new platforms critical failure.
A Never-before-seen Synergistic Ecosystem Composed of 4 Pillars
Sisram's Wellness Group is a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more.
As of 2021 Sisram is operating 4 business lines. The Medical Aesthetics business line, led by Alma, registered a revenue increase of 73.4%. The Injectables business line registered a revenue increase of 50.1% year over year. In 2021, Sisram integrated the activity of Shanghai Foshion Medical System into Sisram, while developing Copulla's digital dentistry service. The Personal Care business line, LMNT by Sisram Medical, is a home-use brand, immersing the essence of wellness into consumers' daily routine.
Looking forward, Mr. Liu Yi, Chairman and Executive Director of Sisram, said: "As a core member of Fosun Pharma's medical device sector, as well as the core platform of Fosun's ecosystem, we have always insisted on customer-centric philosophy and focused on technology and innovation, to continuously improve our product power and competitiveness to respond to the rapid development of the industry. In 2022, based on our charted strategy, we will continue to promote Sisram's ecosystem, and steadily expand the product portfolio and ecological interoperability between Sisram's ecosystem, Fosun Pharma's medical device sector, and even Fosun's greater ecosystem, so as to provide customers with advanced technologies and products through the enhancement of technological applications. We will also promote the sustainable and sound development of the industry by improving clinical applications. In addition, we shall meet the market demand of the aesthetic industry through our diversified product portfolio and market strategy."
Mr. Lior Dayan, CEO of Sisram and Alma, said: "The Group's efforts during 2022 will strategically focus on expanding direct operation in strategic markets to secure market access for both professional and consumer clientele, improve digital infrastructure and tools, drive awareness and preference to our global consumer brand and leverage it to globally introduce new products and services."
About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board.
Sisram Medical - Enhancing Quality of Life
https://www.sisram-medical.com
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding
Rochester Electronics Partners with Kyoto Semiconductor Co., Ltd.
NEWBURYPORT, MA, Mar 9, 2022 - (ACN Newswire) - Rochester Electronics LLC (Massachusetts, USA) is partnering with Kyoto Semiconductor Co., Ltd. (Kyoto, Japan), a leading optical device solution manufacturer with world-class technologies and Japanese quality, to collaborate in offering active and end-of-life (EOL) products to customers.
"We are honored to announce a new partnership with Kyoto Semiconductor, a respected brand within the optical semiconductor landscape. It is through this strategic agreement, that our valued customers can rest assured to have a continued supply of Kyoto Semiconductor optical device solutions, which will not only be certified and guaranteed by Rochester but will also be 100% authorized by the original manufacturer – Kyoto Semiconductor."
- Colin Strother, Executive Vice President at Rochester Electronics LLC
"Kyoto Semiconductor is pleased to collaborate with Rochester Electronics, known for the world's most extensive range of end-of-life (EOL) semiconductors and broadest range of active semiconductors. With this partnership, we extend our customer reach worldwide, with both EOL and active semiconductors. Our products are critical for the optical communication infrastructure and optical sensing equipment used for a long period of time. As we have a large variety of products similar to the EOL'ed products, and we can develop custom products, the partnership with Rochester Electronics will provide helpful solutions for the customers who need to perform long-term maintenance on the infrastructure or equipment.
- Tsuneo Takahashi, CEO at Kyoto Semiconductor Co., Ltd.
Upon this partnership, Kyoto Semiconductor products are available at Rochester Electronics.
About Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre-and postprocessing, and together with Kyoto Semiconductor's unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
For more information, visit: https://www.kyosemi.co.jp/en/
About Rochester Electronics
Rochester Electronics is the world's largest continuous source of semiconductors–100% Authorized by over 70 leading semiconductor manufacturers.
As an original manufacturer stocking distributor, Rochester has over 15 billion devices in stock encompassing more than 200,000-part numbers, providing the world's most extensive range of end-of-life (EOL) semiconductors and broadest range of active semiconductors. As a licensed semiconductor manufacturer, Rochester has manufactured over 20,000 device types. With over 12 billion die in stock, Rochester has the capability to manufacture over 70,000 device types. Rochester offers a full range of manufacturing services including Design, Wafer Processing, Assembly, Test, Reliability, and IP Archiving providing single solutions through to full turnkey manufacturing, enabling faster time-to-market.
Rochester is the Semiconductor Lifecycle Solution. No other company compares to the breadth of Rochester's product selection, value-added services, and manufacturing solutions.
With direct sales and support staff in all major markets, complemented by a network of regional and global authorized channel partners, we aim to meet your needs over the phone or via our e-commerce platforms anytime, anywhere.
For more information visit: www.rocelec.com
Media Contact
Rochester Electronics LLC
Global Marketing Team
Email: [email protected]
Kyoto Semiconductor Co., Ltd.
Naoko Kodama
Media Relations, Kyoto Semiconductor Co., Ltd.
Email: [email protected]
SOURCE: Rochester Electronics LLC
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com
Latest Intelligence
